

# HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

11/12/99



004439969

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))</small>	Attorney Docket No.	2825.1013002
	First Named Inventor or Application Identifier	Hiten D. Madhani
	Express Mail Label No.	EL387865125US

11/12/99  
09/14/99  
U.S. PTO

Title of Invention	TARGETS OF THE MAP KINASE PATHWAY IN THE DEVELOPMENTAL SWITCH IN YEAST
-----------------------	---

<b>APPLICATION ELEMENTS</b> See MPEP chapter 600 concerning utility patent application contents.	<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231
---	---

1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i>  2. <input checked="" type="checkbox"/> Specification <b>[Total Pages [ 16 ] ]</b> <i>(preferred arrangement set forth below)</i> - Descriptive title of the invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to microfiche Appendix - Background of the Invention - Summary of the Invention - Brief Description of the Drawings - Detailed Description - Claim(s) - Abstract of the Disclosure  3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) <b>[Total Sheets [ 11 ] ]</b> <input type="checkbox"/> Formal <input checked="" type="checkbox"/> Informal  4. <input type="checkbox"/> Oath or Declaration/POA <b>[Total Pages [    ] ]</b> a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> <b>[NOTE Box 5 below]</b> i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).  5. <input type="checkbox"/> Incorporation By Reference <i>(useable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	6. <input type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i>  7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) <b>[    ] Pages</b> c. <input type="checkbox"/> Statement verifying identity of above copies  <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2">ACCOMPANYING APPLICATION PARTS</th></tr> <tr> <td style="width: 50%; vertical-align: top;">             8. <input type="checkbox"/> Assignment Papers (cover sheet &amp; documents)              9. <input type="checkbox"/> 37 C.F.R. 3.73(b) Statement <input type="checkbox"/> Power of Attorney                  <i>(when there is an assignee)</i>              10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i>              11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations              12. <input type="checkbox"/> Preliminary Amendment              13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (2)                  <i>(Should be specifically itemized)</i>              14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application,                  status still proper and desired              15. <input type="checkbox"/> Certified Copy of Priority Document(s)                  <i>(if foreign priority is claimed)</i>              16. <input type="checkbox"/> Other: _____           </td><td style="width: 50%;"></td></tr> </table>	ACCOMPANYING APPLICATION PARTS		8. <input type="checkbox"/> Assignment Papers (cover sheet & documents) 9. <input type="checkbox"/> 37 C.F.R. 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i> 10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i> 11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 12. <input type="checkbox"/> Preliminary Amendment 13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (2) <i>(Should be specifically itemized)</i> 14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, status still proper and desired 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 16. <input type="checkbox"/> Other: _____	
ACCOMPANYING APPLICATION PARTS					
8. <input type="checkbox"/> Assignment Papers (cover sheet & documents) 9. <input type="checkbox"/> 37 C.F.R. 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i> 10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i> 11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 12. <input type="checkbox"/> Preliminary Amendment 13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (2) <i>(Should be specifically itemized)</i> 14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, status still proper and desired 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 16. <input type="checkbox"/> Other: _____					

17. <b>If a CONTINUING APPLICATION</b> , check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP)    of prior application No.: Prior application information:    Examiner:    Group Art Unit:	
--	--

18. CORRESPONDENCE ADDRESS					
NAME	Doreen M. Hogle, Esq.				
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.				
ADDRESS	Two Militia Drive				
CITY	Lexington	STATE	MA	ZIP CODE	02421-4799
COUNTRY	USA	TELEPHONE	(781) 861-6240	FAX	(781) 861-9540

Signature	Lisa M. Treannie	Date	November 12, 1999
Submitted by Typed or Printed Name	Lisa M. Treannie	Reg. Number	41,386

DMH/LMT  
11/12/99

-1-

Date: <u>11/12/99</u>	Express Mail Label No. <u>EL387865125US</u>
-----------------------	---

Inventors: Hiten D. Madhani  
Attorney's Docket No.: 2825.1013002

## TARGETS OF THE MAP KINASE PATHWAY IN THE DEVELOPMENTAL SWITCH IN YEAST

### RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application 60/108,399,  
5 filed November 13, 1998, and U.S. Provisional Application 60/114,849, filed January 6,  
1999. The entire teachings of these applications are incorporated herein by reference.

### GOVERNMENT SUPPORT

Work described herein was supported, in whole or in part, by National Institutes  
of Health Grant Number GM 40266. The United States Government has certain rights  
10 in the invention.

### BACKGROUND OF THE INVENTION

Two related developmental events, haploid invasive growth and diploid  
pseudohyphal development, are controlled by the Kss1 MAP kinase pathway in yeast.  
Haploid invasive growth occurs on rich medium, whereas filamentation in the diploid  
15 cell type requires nitrogen starvation. The diploid pathway results in dramatic cell  
elongation, which is not seen in haploids. These pathways serve as models for similar  
transitions in pathogenic fungi.

## SUMMARY OF THE INVENTION

Wild yeast are often found in association with plants, particularly rotting fruit. Not surprisingly, many bacterial and plant fungal pathogens secrete pectin-degrading enzymes, including polygalacturonases. These are thought to be key virulence factors.

- 5 In the bacterial pathogen *Erwinia chrysanthemi* there exists an elaborate interaction between the host and the pathogen in which the breakdown product of pectin, galacturonic acid, signals large changes in the expression of the pectinolytic machinery. To examine whether a similar interaction with the host might be occurring in yeast, global profiling experiments of gene expression in the presence of polygalacturonic acid  
10 or galacturonic acid were carried out.

- Described herein is assessment of targets of the MAP kinase (MAPK) pathway in the developmental switch between haploid invasive growth and diploid pseudohyphal development in yeast, and identification of genes that show strong regulation by a MAPK pathway-specific transcription factor, Tec1. Also described herein are results of  
15 examination of expression profiles after administration of polygalacturonic acid (the main component of pectin) or galacturonic acid (the breakdown product of pectin), as well as the results of detailed studies of PGUI, a pectinase, which was shown to be the most strongly regulated target of the MAPK pathway.

- Also described are global profiling experiments of gene expression in yeast  
20 which were carried out to examine whether a host-yeast interaction occurs in which the breakdown product of pectin signals or causes changes in the expression of components of the pectinolytic machinery. As discussed herein, results of these profiling experiments showed that both polygalacturonic acid and galacturonic acid altered gene expression in yeast, and that the patterns were distinct from those that would have been  
25 expected from the effects of all other sugars that have been studied in yeast (e.g., glucose, galactose, maltose, etc.), demonstrating the specificity of the response. Galacturonic acid, the breakdown product of pectin, was shown to cause strong repression of TOT10/YEL033W, a gene which is turned on in the filamentation MAPK pathway and is required for invasion and filamentation. Thus, a regulatory circuit in

yeast, in which a signal from the host (in the form of or mediated by galacturonic acid) feeds back on the filamentation/invasion pathway, has been identified, and a specific interaction between yeast and its host (e.g., a plant host) has been demonstrated for the first time.

5           As a result of the work described herein, targets of the MAPK pathway in fungi (e.g., yeast) and, particularly, genes that show strong regulation by Tec1, a MAPK pathway-specific transcription factor, have been identified. These genes and their interaction with or regulation by Tec1 can be targeted in a method of modulating (inhibiting or enhancing) the developmental switch between haploid invasive growth  
10 and diploid filamentation. Compounds or molecules which modulate these genes, directly or through their regulation by Tec1, can be identified by means, for example, of an assay in which one or more of the genes (e.g., a gene encoding PGUI) is expressed in an appropriate host cell and the effects of a candidate modulator (inhibitor or enhancer) on its expression are determined. Candidate modulators shown to decrease expression  
15 are inhibitors of a gene shown, as described herein, to be regulated by Tec1; candidate modulators shown to increase expression are enhancers of such a Tec1-regulated gene. In addition, the TOT10/YEL033W gene, shown, as described herein, to participate in a regulatory circuit between yeast and a host (e.g., a plant host) can be targeted to modulate (decrease or increase) yeast-host interaction. It can be targeted, for example,  
20 to inhibit yeast invasion and/or filamentation and, thus, to inhibit adverse effects of fungi, including pathogenic and nonpathogenic yeast. Inhibitors (or enhancers) of TOT10/YEL033W can be identified, for example, in an assay in which the gene is expressed in an appropriate host cell and the effects of candidate inhibitors (or  
25 enhancers) are assessed. Inhibition of TOT10/YEL033W, directly or indirectly (e.g., by inhibiting a gene or the product of a gene with which TOT10/YEL033W interacts) will result in inhibition of invasion and/or filamentation. Inhibitors and enhancers of genes regulated by Tec1 and inhibitors of TOT10/YEL033W are the subject of this invention.

Compounds or molecules which activate or inhibit PGUI can also be identified. For example, activators of this pectinase can be identified by expressing PGUI in an

appropriate host cell (e.g., a bacterial or yeast cell), contacting the cells with (e.g., by culturing them in the presence of) candidate activators (compounds or molecules to be assessed for their effects on PGUI activity) and determining their effect on PGUI (e.g., whether they enhance or activate PGUI expression or activity, repress or decrease PGUI expression or activity or have no effect). Compounds which enhance or activate PHUI expression or activity are activators; those which repress or decrease its expression or activity are inhibitors). Activators and inhibitors of PGUI are also the subject of this invention.

Also the subject of this invention is a method of inhibiting (totally or partially) invasion of a host, particularly a plant host by a fungus (i.e., a method of inhibiting fungal invasion of a host). In the method, a compound or molecule which inhibits the MAPK pathway or specifically inhibits TOT10/YELO33W is applied to a host (e.g., by application to a plant surface) in such a manner that it contacts the fungus (e.g., the yeast) and inhibits one or more components of the MAPK pathway, such as TOT10/YELO33W. For example, an inhibitor can be a compound which binds and inhibits TOT10/YELO33W; galacturonic acid; or a mimic of galacturonic acid which represses TOT10/YELO33W. In a specific embodiment, the method of inhibiting fungal invasion of a host comprises contacting a fungus (e.g., a yeast) with a compound which inhibits the MAPK pathway and/or inhibits TOT10/YELO33W, in sufficient quantity that inhibition of the MAPK pathway and/or inhibition of TOT10/YELO33W occurs, thereby inhibiting fungal invasion of the host. In a further embodiment, the host is a plant and the compound is applied to a plant surface (e.g., root, leaf, stem) or seed in such a manner that it contacts the fungus and inhibits (totally or partially) the ability of the fungus to invade.

## 25 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows genetic expression profiles of 18 genes regulated by the filamentation MAPK pathway.

Figure 2 lists MAPK pathway targets.

Figure 3 summarizes results of systematic knockout experiments.

Figure 4 is a photograph of results of an assay showing that filamentation MAPK pathway controls pectinolysis via PGUI.

Figure 5 shows genes selectively induced by the plant-specific carbohydrate polygalacturonic acid and its hydrolysis product.

Figure 6 shows genes selectively repressed by the plant-specific carbohydrate polygalacturonic acid and its hydrolysis product.

Figure 7 is a compilation of MAPK data, sorted as TEC1-high copy/*tec1*Δ.

Figure 8 shows results of profiling experiments with polygalacturonic acid (PGA) and galacturonic acid (GA), sorted by PGA/YPD.

Figure 9 shows results of profiling experiments with polygalacturonic acid (PGA) and galacturonic acid (GA), sorted by GA/YPD.

Figure 10 shows a flow chart of homologous genes induced by the filamentation and mating MAPK pathways.

Figure 11 shows a listing of genes whose expression is reduced in *STE12*<sup>-</sup>, *STE7*<sup>-</sup> but show greater than double an effect with *Tec1*.

## DETAILED DESCRIPTION OF THE INVENTION

Described herein is work carried out to identify and study the targets of the MAP kinase pathway in order to understand how signaling cascades control a developmental switch in this *Saccharomyces cerevisiae* model system. The pathway consists of four kinases *Ste20* (PAK), *Ste11* (MEKK), *Ste7* (MEK) and *Kss1* (MAPK), which display both positive and negative control over the pathway, as well as a heterodimeric transcription factor *Tec1-STE12*. *STE7*, *STE11* and *STE20* also participate in the yeast mating MAPK pathway. Global expression patterns in haploid cells under rich medium conditions were examined in the following mutants: wild type *tec1*Δ *Ste12*Δ, *Ste7*Δ, *TEC1*-overexpression, and *STE11-4* (an activated mutant of the MEKK). Expression profiling was carried out using nucleic acid arrays (chips) such as described in

WO95/11995. One chip set was used per sample (chips with obvious defects were redone).

18 genes were identified that show strong regulation by the pathway-specific transcription factor Tec1 (i.e. 3.5-20X difference in expression comparing TEC1-overexpression to *tec1* $\Delta$ ). Almost all of these also show a consistent dependency on STE7, STE7, and STE12. One gene that was known previously to be regulated by the pathway, FLO11 (which encodes a cell surface protein required for pseudohyphal growth) is the second-most strongly regulated target. Detailed studies were performed on one of these targets, PGU1, which encodes a secreted carbohydrate-destroying enzyme. This enzyme breaks down a key component of plant cell walls, polygalacturonic acid (which is the main component of pectin).

Remarkably, galacturonic acid, the breakdown product of pectin, causes the strong repression of a gene, TOT10/YEL033W, which is turned on in the filamentation MAPK pathway and which these results have shown is required for invasion and filamentation. Thus, work described herein has identified a new regulatory circuit in yeast in which a signal from the host feeds back on the filamentation/invasion pathway. This is the first demonstration of a specific interaction between yeast and its plant host. Figures 1-11 show the data in detail.

Work described herein provides an analysis of data from haploid strains grown in rich medium conditions, and in diploid cells under nitrogen starvation conditions; that is, the conditions that promote pseudohyphal cells. Portion of this work was carried out to assess whether pseudohyphal cells respond to MAPK signaling differently compared to haploid cells. The experiments described compare the expression of strains overexpressing the transcription factor Tec1 to those lacking it. They extend the assessment of targets of the MAP kinase pathway in a yeast developmental switch in haploid cells to examination of signaling in diploid cells. The data (Tables 1 and 2) were analyzed using a floor of 20 and a maximum-minimum filter of 80. Genes showing a greater than two-fold change in duplicate samples are listed. The results indicate that a largely different set of genes is induced by the MAPK

pathway during pseudohyphal conditions. One striking exception is the *FLO11* gene, which is the gene most strongly induced both in haploids and diploids by the pathway. The other genes fall mainly into the categories of cell-cycle regulated genes (such as histones and PCNA), nitrogen scavenging factors (e.g., Dur3, Car2). A number of other  
5 genes are regulated that do not at present fit into any pattern.

Accordingly, the invention relates to a method of inhibiting invasion of a host by a fungus, comprising contacting the fungus with a compound which inhibits expression of a gene expressed in the filamentation MAPK pathway and which enhances the filamentation MAPK pathway, in sufficient quantity that inhibition of the  
10 expression of the gene occurs, thereby inhibiting invasion of the host by the fungus. In one embodiment, the host is a plant, and the compound is applied to a plant surface (e.g., a leaf, a root, a stem, a flower) in such a manner that it contacts the fungus. An effective amount of the compound can be determined empirically by assessing expression levels of the gene to be inhibited. In a preferred embodiment, the gene is  
15 TOT10/YELO33W. In one embodiment, the fungus is a yeast, such as *Saccharomyces cerevisiae*.

Agents for use in the methods of the invention include nucleic acid molecules (e.g., antisense), polypeptides and proteins, antibodies and small organic molecules. Suitable formulations of agents for use in this invention can include, for example,  
20 powders, liquids, aerosols, gels and other formulations known to the skilled artisan. The present invention also pertains to pharmaceutical compositions comprising agents identified according to the invention for use in the treatment of fungal invasion. For instance, the agent identified according to the present invention can be formulated with a physiologically acceptable medium to prepare a pharmaceutical composition. The  
25 particular physiological medium may include, but is not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions. The optimum concentration of the active ingredient(s) in the chosen medium can be determined empirically, according to procedures well known to medicinal chemists, and will depend on the ultimate pharmaceutical formulation



desired. In organisms other than plants, methods of administration of pharmaceutical compositions include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal. Other suitable methods of introduction can also include rechargeable or biodegradable devices and slow release polymeric devices. The pharmaceutical compositions of this invention can also be administered as part of a combinatorial therapy with other agents.

The invention also relates to a method of inhibiting invasion of a host by a fungus, comprising contacting the fungus with a compound which alters activity of a gene product encoded by a gene expressed in the filamentation MAPK pathway, in sufficient quantity that alteration of the activity of said gene product occurs, thereby inhibiting invasion of the host by the fungus. For example, if the gene is one whose expression enhances (e.g., increases or potentiates) the filamentation MAPK pathway (e.g., a positive regulator of the pathway), then the compound should inhibit the expression of that gene. As used herein, inhibition is intended to include both qualitative and quantitative reduction, including complete abolishment. Conversely, if the gene is one whose expression inhibits (e.g., decreases or interferes with) the filamentation MAPK pathway (e.g., a negative regulator of the pathway), then the compound should enhance the expression of that gene. As used herein, enhancement is intended to include any qualitative or quantitative increase. For example, the gene can be TOT10/YELO33W.

Expression vectors for use in the invention typically contain a nucleic acid sequence of a gene of interest operably linked to at least one regulatory sequence. "Operably linked" is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allow expression of the nucleic acid sequence. Regulatory sequences are art-recognized and can be selected according to the host cell and type of expression (e.g., constitutive) to be obtained. Accordingly, the term "regulatory sequence" includes promoters, enhancers, and other expression control elements which are described in Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). It should be understood that

the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed.

Prokaryotic and eukaryotic host cells transfected by the described vectors are also provided by this invention. For instance, cells which can be transfected with the  
5 vectors of the present invention include, but are not limited to, bacterial cells such as *E. coli*, insect cells (baculovirus), or mammalian cells such as Chinese hamster ovary cells (CHO). Ligating the polynucleotide sequence into a gene construct, such as an expression vector, and transforming or transfecting into hosts, either eukaryotic (avian, insect or mammalian) or prokaryotic (bacterial cells), are standard procedures (see, for  
10 example, Broach, *et al.*, *Experimental Manipulation of Gene Expression*, ed. M. Inouye (Academic Press, 1983) p. 83; *Molecular Cloning: A Laboratory Manual*, 2nd Ed., ed. Sambrook *et al.* (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17).

The invention also relates to a method of identifying an agent which inhibits the filamentation MAPK pathway in a fungus, comprising the steps of providing an  
15 expression vector comprising a nucleic acid molecule of a gene which is expressed in the filamentation MAPK pathway; transforming a suitable host cell with said expression vector under conditions suitable for expression of said gene contacting said host cell with an agent to be tested; and comparing the expression of said gene in the presence of the agent with the expression of said gene in the absence of said agent, wherein if the  
20 expression of said gene is lower in the presence of the agent than in the absence of the agent, then the agent is an inhibitor of the filamentation MAPK pathway in a fungus. In one embodiment, the gene is TOT10/YELO33W.

Genes which are expressed in the filamentation MAPK pathway can be identified by standard methods in the art. In one embodiment, the gene is identified by  
25 expression profiling as having repressed expression in the presence of galacturonic acid as compared with in the absence of galacturonic acid. In another embodiment, the gene can be identified by expression profiling as being expressed in haploid fungal cells and not expressed in diploid fungal cells, or as being repressed by Tec1 expression.

The invention also relates to a method of inhibiting fungal filamentation, comprising contacting the fungus with a compound which inhibits expression of a gene expressed in the filamentation MAPK pathway, in sufficient quantity that inhibition of the expression of the gene occurs, thereby inhibiting filamentation by the fungus.

5       The invention further relates to a method of identifying an agent which modulates PGUI gene expression, comprising the steps of providing an expression vector comprising a nucleic acid molecule encoding PGUI; transforming a suitable host cell with said expression vector under conditions suitable for expression of PGUI; contacting said host cell with an agent to be tested; and comparing the expression of  
10 PGUI in the presence of the agent with the expression of PGUI in the absence of said agent, wherein a difference in the expression of PGUI in the presence of the agent as compared with in the absence of the agent indicates that the agent modulates PGUI expression.

15       The invention also includes a method of reducing the adverse effects of fungal invasion of a host, comprising administering to the host an effective amount of an agent which inhibits PGUI expression in the fungus.

20       The invention further includes a method of inhibiting invasion of a host by a fungus, comprising contacting the fungus with a compound which enhances expression of a gene expressed in the filamentation MAPK pathway and which inhibits the pathway, in sufficient quantity that enhancement of the expression of the gene occurs, thereby inhibiting invasion of the host by the fungus.

25       While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Table 1

**PSEUDOHYPHAL CONDITIONS**

gene	Information
<i>FLO11 (YIR019C)</i>	GPI-anchored cell surface flocculin req'd for invasion
<i>DUR3 (YHL016C)</i>	Urea Permease
<i>HTA2 (YBL003C)</i>	Histone H2A
<i>HTB2 (YBL002W)</i>	Histone H2B
<i>ORF YNL300W</i>	GPI-anchored S/T rich protein
<i>ORF YOL162W</i>	Allantoate permease family
<i>ORF YLL057C</i>	Similar to <i>E. coli</i> taurine dioxygenase
<i>SVS1 (YPL163C)</i>	S/T rich protein req'd for vanadate resistance
<i>ORF YOL163W</i>	Allantoate permease family
<i>CAR2 (YLR438W)</i>	Ornithine aminotransferase, arginine catabolism
<i>TSL1 (YML100W)</i>	Trehalose-6-phosphate synthase/phosphatase subunit
<i>PRY2 (YKR013W)</i>	Homolog of Plant Pathogen-Induced Gene
<i>POL30 (YBR088C)</i>	PCNA, DNA Replication, Repair and Cell Cycle Factor
<i>PDC6 (YGR087C)</i>	Pyruvate decarboxylase: isobutyl alcohol formation
<i>ORF YOR247W</i>	S/T rich protein related to Svs1

Floor=20, max-min>80,max/min>2, TEC1HC/*tec1*Δ>2 for both chip sets

Table 2

## PSEUDOHYPHAL CONDITIONS

gene	tec1KO A	TEC1HC A	tec1KO B	tec1HC B
<i>FLO11 (YIR019C)</i>	46	505	61	471
<i>DUR3 (YHL016C)</i>	20	105	53	116
<i>HTA2 (YBL003C)</i>	29	145	32	180
<i>HTB2 (YBL002W)</i>	122	559	184	617
<i>ORF YNL300W</i>	349	1281	340	1031
<i>ORF YOL162W</i>	44	160	66	151
<i>ORF YLL057C</i>	64	227	63	243
<i>SVS1 (YPL163C)</i>	129	453	112	370
<i>ORF YOL163W</i>	53	160	43	179
<i>CAR2 (YLR438W)</i>	49	138	43	165
<i>TSL1 (YML100W)</i>	148	399	175	373
<i>PRY2 (YKR013W)</i>	436	1148	472	1012
<i>POL30 (YBR088C)</i>	129	313	103	261
<i>PDC6 (YGR087C)</i>	129	276	78	270
<i>ORF YOR247W</i>	669	1372	485	1323

Floor=20, max-min>80,max/min>2, TEC1HC/*tec1*Δ>2 for both chip sets

## CLAIMS

What is claimed is:

1. A method of inhibiting invasion of a host by a fungus, comprising contacting the fungus with a compound which inhibits expression of a gene expressed in the filamentation MAPK pathway and which enhances said pathway, in sufficient quantity that inhibition of the expression of said gene occurs, thereby inhibiting invasion of the host by the fungus.
2. A method according to Claim 1 wherein the gene is TOT10/YELO33W.
3. A method according to Claim 1 wherein the host is a plant and the compound is applied to a plant surface in such manner that it contacts the fungus.
4. A method according to Claim 1 wherein the fungus is a yeast.
5. A method of inhibiting invasion of a host by a fungus, comprising contacting the fungus with a compound which inhibits activity of a gene product encoded by a gene expressed in the filamentation MAPK pathway, in sufficient quantity that inhibition of the activity of said gene product occurs, thereby inhibiting invasion of the host by the fungus.
6. A method according to Claim 5 wherein the gene is TOT10/YELO33W.
7. A method according to Claim 5 wherein the host is a plant and the compound is applied to a plant surface in such manner that it contacts the fungus.
8. A method according to Claim 5 wherein the fungus is a yeast.

9. A method of identifying an agent which inhibits the filamentation MAPK pathway in a fungus, comprising the steps of:
- a) providing an expression vector comprising a nucleic acid molecule of a gene which is expressed in the filamentation MAPK pathway;
  - 5 b) transforming a suitable host cell with said expression vector under conditions suitable for expression of said gene;
  - c) contacting said host cell with an agent to be tested; and
  - d) comparing the expression of said gene in the presence of the agent with the expression of said gene in the absence of said agent,
- 10 wherein if the expression of said gene is lower in the presence of the agent than in the absence of the agent, then the agent is an inhibitor of the filamentation MAPK pathway in a fungus.
10. A. method according to Claim 9, wherein the gene is TOT10/YELO33W.
11. A method according to Claim 9, wherein the fungus is yeast.
- 15 12. A method according to Claim 9, wherein the gene is identified by expression profiling as having repressed expression in the presence of galacturonic acid.
13. A method according to Claim 9, wherein the gene is identified by expression profiling as being expressed in haploid fungal cells and not expressed in diploid fungal cells.
- 20 14. A method of inhibiting fungal filamentation, comprising contacting the fungus with a compound which inhibits expression of a gene expressed in the filamentation MAPK pathway, in sufficient quantity that inhibition of the expression of said gene occurs, thereby inhibiting filamentation by the fungus.

15. A method of identifying an agent which modulates PGUI gene expression, comprising the steps of:
- a) providing an expression vector comprising a nucleic acid molecule encoding PGUI;
  - 5 b) transforming a suitable host cell with said expression vector under conditions suitable for expression of PGUI;
  - c) contacting said host cell with an agent to be tested; and
  - d) comparing the expression of PGUI in the presence of the agent with the expression of PGUI in the absence of said agent,
- 10 wherein a difference in the expression of PGUI in the presence of the agent as compared with in the absence of the agent indicates that the agent modulates PGUI expression.
16. A method of reducing the adverse effects of fungal invasion of a host, comprising administering to the host an effective amount of an agent which
- 15 inhibits PGUI expression in the fungus.
17. A method of inhibiting invasion of a host by a fungus, comprising contacting the fungus with a compound which enhances expression of a gene expressed in the filamentation MAPK pathway and which inhibits said pathway, in sufficient quantity that enhancement of the expression of said gene occurs, thereby
- 20 inhibiting invasion of the host by the fungus.
18. A method according to Claim 1 wherein the fungus is a yeast.



## TARGETS OF THE MAP KINASE PATHWAY IN THE DEVELOPMENTAL SWITCH IN YEAST

### ABSTRACT OF THE DISCLOSURE

Assessment of targets of the MAP kinase pathway in the developmental switch  
5 between haploid invasive growth and diploid pseudohyphal development in fungi, and  
identification of genes that show strong regulation by a MAPK pathway-specific  
transcription factor, Tec1, are described. Also described are methods of identifying an  
agent which inhibits the filamentation MAPK pathway in a fungus, and methods of  
inhibiting filamentation of a fungus or invasion of a host by a fungus.

# Genetic Expression Profiles of 18 Genes Regulated by the Filamentation MAPK Pathway




Figure 1

# MAPK Targets Include Proteins Known or Predicted to Enter the Secretory Pathway

<i>PGU1</i>	secreted endopolygalacturonase
<i>FLO11</i>	GPI-linked cell surface adhesion factor
<i>TOT10/YEL033W</i>	novel
<i>SRD1</i>	Zinc finger protein
<i>TOT12/YKR105C</i>	putative permease
<i>TOT13/YOR225W</i>	putative membrane protein
<i>FLO5</i>	GPI-linked cell surface adhesion factor
<i>DDR48</i>	cell surface protein
<i>TOT11/YLR042C</i>	GPI-linked cell surface protein
<i>TOT7/YER158C</i>	Homolog of mating morphogenesis protein Afr1
<i>TOT8/YIL117C</i>	Homolog of Chitin Synthase III subunit
<i>TOT20/YHL049C</i>	telomeric protein family member
<i>TOT15/YLR434C</i>	novel
<i>TOT14/YBR113W</i>	putative membrane protein
<i>TOT9/YIR013C</i>	Zinc finger protein
<i>PHO84</i>	phosphate transporter, sugar permease family
<i>KTR2</i>	protein mannosyltransferase homolog
<i>SJH1</i>	Sac1-related inositol phosphate 5-phosphatase homolog

Figure 2

# Sytematic Knockout Experiments


GENE	Haploid Invasion	Diploid Filamentation
<i>PGU1</i>	+++	+++
<i>FLO11</i>	-	-
<i>TOT10/YEL033W</i>	+	+
<i>SRD1</i>	ND	ND
<i>TOT12/YKR105C</i>	+++	+++
<i>TOT13/YOR225W</i>	+++	+++
<i>FLO5</i>	+++	+++
<i>DDR48</i>	+++	+++
<i>TOT11/YLR042C</i>	+++	+++
<i>TOT7/YER158C</i>	+++	+++
<i>TOT8/YIL117C</i>	+++	+++
<i>TOT20/YHL049C</i>	ND	ND
<i>TOT15YLR434C</i>	+++	+++
<i>TOT14/YBR113W</i>	+++	+++
<i>TOT9/YIR013C</i>	+++	+++
<i>PHO84</i>	+++	+++
<i>KTR2</i>	+++	+++
<i>SJH1</i>	+++	+++

Figure 3

# Filamentation MAPK Pathway Controls Pectinolysis via *PGU1*

epistasis

null phenotypes



2 days

7 days

Figure 4

# Gene Induction by the Plant-Specific Carbohydrate Polygalacturonic Acid and Its Hydrolysis Product

## Genes Selectively Induced by Polygalacturonic Acid

gene	GA/-	PGA/-	Protein Information
<i>XBP1</i>	2.40	6.65	Stress-induced transcriptional repressor
<i>YHR217C</i> (Δf)	1.30	6.00	Protein of unknown function
<i>YPL080C</i>	2.80	5.70	Protein of unknown function
<i>YPR098C</i>	1.16	5.49	Protein of unknown function
<i>YHL040C</i>	2.04	5.00	Putative MFS Permease
<i>YOL080C</i>	1.35	4.74	Protein with similarity to Rnh70p and Pan2p
<i>PHO84</i>	1.39	4.70	phosphate transport, sugar permease homolog*
<i>YMR293C</i>	1.29	4.07	Protein with similarity to amidase
<i>YLR184W</i>	1.33	3.24	Protein of unknown function
<i>YIL011W</i>	1.01	3.01	Protein with similarity to PAU1 family
<i>CYT1</i>	1.02	2.82	Cytochrome c1
<i>ATP11</i>	1.29	2.65	F1-ATP synthase assembly protein
<i>YOR091W</i>	1.17	2.51	Protein of unknown function
<i>PAU3</i>	1.02	2.46	Stress-induced protein of the PAU1 family
<i>SKO1</i>	0.47	2.35	ATF/CREB transcriptional repressor
<i>MSI4</i>	0.73	2.06	Rab guanine nucleotide dissociation inhibitor
Regulated by Filamentation MAPK Pathway*			

## Genes Selectively Induced by Galacturonic Acid

gene	GA/-	PGA/-	Protein Information
<i>VPS1</i>	4.03	1.69	Vacuolar sorting protein, dynamin GTPase

Figure 5

# Gene Repression by the Plant-Specific Carbohydrate Polygalacturonic Acid and its Hydrolysis Product

## Genes Selectively Repressed by Polygalacturonic Acid

gene	GA/-	PGA/-	Protein Information
<i>COP1/SEC33</i>	0.63	0.17	alpha subunit of coatamer complex
<i>YOL002C</i>	1.36	0.18	Protein of unknown function
<i>YDL173W</i>	0.96	0.24	Protein of unknown function
<i>COQ2</i>	1.37	0.25	coenzyme Q (ubiquinone) biosynthesis
<i>YIL176C (-f)</i>	0.86	0.30	Protein with similarity to PAU1 family
<i>YFL032W</i>	0.80	0.30	Protein of unknown function
<i>RPS33A</i>	1.10	0.34	Ribosomal protein S28A
<i>ARC35</i>	1.25	0.39	Component of ARP2/3 complex
<i>RPS26A</i>	0.87	0.39	Ribosomal protein S26A
<i>RPS10A</i>	1.02	0.46	Ribosomal protein S10A

## Genes Selectively Repressed by Galacturonic Acid

gene	GA/-	PGA/-	Protein Information
<i>YEL033W</i>	0.12	0.38	Protein of unknown function*
<i>VID24</i>	0.24	1.46	Vacuolar import and degradation of Fbp1
<i>NDC1</i>	0.29	1.02	Spindle pole body duplication factor
<i>SKO1</i>	0.47	2.35	ATF/CREB transcriptional repressor

\*Regulated by the Filamentation MAPK Pathway

Figure 6

Note that the details of the list are slightly different from some of the figures because these data were floored and floored slightly differently.

MARK DATA	TECHNIC	STEL-14	VED THE	TECHNIC	STEL-14	VED THE
282	47	113	2020	47	113	2020
283	48	114	2021	48	114	2021
284	49	115	2022	49	115	2022
285	50	116	2023	50	116	2023
286	51	117	2024	51	117	2024
287	52	118	2025	52	118	2025
288	53	119	2026	53	119	2026
289	54	120	2027	54	120	2027
290	55	121	2028	55	121	2028
291	56	122	2029	56	122	2029
292	57	123	2030	57	123	2030
293	58	124	2031	58	124	2031
294	59	125	2032	59	125	2032
295	60	126	2033	60	126	2033
296	61	127	2034	61	127	2034
297	62	128	2035	62	128	2035
298	63	129	2036	63	129	2036
299	64	130	2037	64	130	2037
300	65	131	2038	65	131	2038
301	66	132	2039	66	132	2039
302	67	133	2040	67	133	2040
303	68	134	2041	68	134	2041
304	69	135	2042	69	135	2042
305	70	136	2043	70	136	2043
306	71	137	2044	71	137	2044
307	72	138	2045	72	138	2045
308	73	139	2046	73	139	2046
309	74	140	2047	74	140	2047
310	75	141	2048	75	141	2048
311	76	142	2049	76	142	2049
312	77	143	2050	77	143	2050
313	78	144	2051	78	144	2051
314	79	145	2052	79	145	2052
315	80	146	2053	80	146	2053
316	81	147	2054	81	147	2054
317	82	148	2055	82	148	2055
318	83	149	2056	83	149	2056
319	84	150	2057	84	150	2057
320	85	151	2058	85	151	2058
321	86	152	2059	86	152	2059
322	87	153	2060	87	153	2060
323	88	154	2061	88	154	2061
324	89	155	2062	89	155	2062
325	90	156	2063	90	156	2063
326	91	157	2064	91	157	2064
327	92	158	2065	92	158	2065
328	93	159	2066	93	159	2066
329	94	160	2067	94	160	2067
330	95	161	2068	95	161	2068
331	96	162	2069	96	162	2069
332	97	163	2070	97	163	2070
333	98	164	2071	98	164	2071
334	99	165	2072	99	165	2072
335	100	166	2073	100	166	2073
336	101	167	2074	101	167	2074
337	102	168	2075	102	168	2075
338	103	169	2076	103	169	2076
339	104	170	2077	104	170	2077
340	105	171	2078	105	171	2078
341	106	172	2079	106	172	2079
342	107	173	2080	107	173	2080
343	108	174	2081	108	174	2081
344	109	175	2082	109	175	2082
345	110	176	2083	110	176	2083
346	111	177	2084	111	177	2084
347	112	178	2085	112	178	2085
348	113	179	2086	113	179	2086
349	114	180	2087	114	180	2087
350	115	181	2088	115	181	2088
351	116	182	2089	116	182	2089
352	117	183	2090	117	183	2090
353	118	184	2091	118	184	2091
354	119	185	2092	119	185	2092
355	120	186	2093	120	186	2093
356	121	187	2094	121	187	2094
357	122	188	2095	122	188	2095
358	123	189	2096	123	189	2096
359	124	190	2097	124	190	2097
360	125	191	2098	125	191	2098
361	126	192	2099	126	192	2099
362	127	193	2100	127	193	2100
363	128	194	2101	128	194	2101
364	129	195	2102	129	195	2102
365	130	196	2103	130	196	2103
366	131	197	2104	131	197	2104
367	132	198	2105	132	198	2105
368	133	199	2106	133	199	2106
369	134	200	2107	134	200	2107
370	135	201	2108	135	201	2108
371	136	202	2109	136	202	2109
372	137	203	2110	137	203	2110
373	138	204	2111	138	204	2111
374	139	205	2112	139	205	2112
375	140	206	2113	140	206	2113
376	141	207	2114	141	207	2114
377	142	208	2115	142	208	2115
378	143	209	2116	143	209	2116
379	144	210	2117	144	210	2117
380	145	211	2118	145	211	2118
381	146	212	2119	146	212	2119
382	147	213	2120	147	213	2120
383	148	214	2121	148	214	2121
384	149	215	2122	149	215	2122
385	150	216	2123	150	216	2123
386	151	217	2124	151	217	2124
387	152	218	2125	152	218	2125
388	153	219	2126	153	219	2126
389	154	220	2127	154	220	2127
390	155	221	2128	155	221	2128
391	156	222	2129	156	222	2129
392	157	223	2130	157	223	2130
393	158	224	2131	158	224	2131
394	159	225	2132	159	225	2132
395	160	226	2133	160	226	2133
396	161	227	2134	161	227	2134
397	162	228	2135	162	228	2135
398	163	229	2136	163	229	2136
399	164	230	2137	164	230	2137
400	165	231	2138	165	231	2138
401	166	232	2139	166	232	2139
402	167	233	2140	167	233	2140
403	168	234	2141	168	234	2141
404	169	235	2142	169	235	2142
405	170	236	2143	170	236	2143
406	171	237	2144	171	237	2144
407	172	238	2145	172	238	2145
408	173	239	2146	173	239	2146
409	174	240	2147	174	240	2147
410	175	241	2148	175	241	2148
411	176	242	2149	176	242	2149
412	177	243	2150	177	243	2150
413	178	244	2151	178	244	2151
414	179	245	2152	179	245	2152
415	180	246	2153	180	246	2153
416	181	247	2154	181	247	2154
417	182	248	2155	182	248	2155
418	183	249	2156	183	249	2156
419	184	250	2157	184	250	2157
420	185	251	2158	185	251	2158
421	186	252	2159	186	252	2159
422	187	253	2160	187	253	2160
423	188	254	2161	188	254	2161
424	189	255	2162	189	255	2162
425	190	256	2163	190	256	2163
426	191	257	2164	191	257	2164
427	192	258	2165	192	258	2165
428	193	259	2166	193	259	2166
429	194	260	2167	194	260	2167
430	195	261	2168	195	261	2168
431	196	262	2169	196	262	2169
432	197	263	2170	197	263	2170
433	198	264	2171	198	264	2171
434	199	265	2172	199	265	2172
435	200	266	2173	200	266	2173
436	201	267	2174	201	267	2174
437	202	268	2175	202	268	2175
438	203	269	2176	203	269	2176
439	204	270	2177	204	270	2177
440	205	271	2178	205	271	2178
441	206	272	2179	206	272	2179
442	207	273	2180	207	273	2180
443	208	274	2181	208	274	2181
444	209	275	2182	209	275	2182
445	210	276	2183	210	276	2183
446	211	277	2184	211	277	2184
447	212	278	2185	212	278	2185
448	213	279	2186	213	279	2186
449	214	280	2187	214	280	2187
450	215	281	2188	215	281	2188
451	216	282	2189	216	282	2189
452	217	283	2190	217	283	2190
453	218	284	2191	218	284	2191
454	219	285	2192	219	285	2192
455	220	286	2193	220	286	2193
456	221	287	2194	221	287	2194
457	222	288	2195	222	288	2195
458	223	289	2196	223	289	2196
459	224	290	2197	224	290	2197
460	225	291	2198	225	291	2198
461	226	292	2199	226	292	2199
462	227	293	2200	227	293	2200
463	228	294	2201	228	294	2201
464	229	295	2202	229	295	2202
465	230	296	2203	230	296	2203
466	231	297	2204	231	297	2204
467	232	298	2205	232	298	2205
468	233	299	2206	233	299	2206
469	234	300	2207	234	300	2207
470	235	301	2208	235	301	2208
471	236	302	2209	236	302	2209
472	237	303	2210	237	303	2210
473	238	304	2211	238	304	2211
474	239	305	2212	239	305	2212
475	240	306	2213	240	306	2213
476	241	307	2214	241	307	2214
477	242	308	2215	242	308	2215
478	243	309	2216	243	309	2216
479	244	310	2217	244	310	2217
480	245	311	2218	245	311	2218
481	246	312	2219	246	312	2219



NAME=GA						
gene	YPD	GA	PGA	GA/YPD	PGA/YPD	
ORF YIL101C	20	48	133	2.40	6.65	
ORF YLR344W exon 1 (_i)	33	138	208	4.18	6.30	
ORF YHR217C (_r_i)	20	29	120	1.45	6.00	
ORF YHR217C (_f)	20	26	120	1.30	6.00	
ORF YPL080C	20	56	114	2.80	5.70	
ORF YPR098C	37	43	203	1.16	5.49	
ORF YHL040C	27	55	135	2.04	5.00	
ORF YOL080C	23	31	109	1.35	4.74	
PHO84 (YML123C)	33	46	155	1.39	4.70	
ORF YMR293C	28	36	114	1.29	4.07	
ORF YLR184W	66	88	214	1.33	3.24	
ORF YIL011W	153	154	460	1.01	3.01	
ORF YJR027W exon 2 (_f)	156	351	459	2.25	2.94	
CYT1 (YOR065W)	91	93	257	1.02	2.82	
ORF YLL025W (_f)	251	355	693	1.41	2.76	
ORF YML039W exon 2 (_f)	192	486	524	2.53	2.73	
ATP11 (YNL315C)	51	66	135	1.29	2.65	
ORF YOR091W	59	69	148	1.17	2.51	
ORF YMR143W exon 1 (_i)	385	895	964	2.32	2.50	
ORF YJR029W exon 2 (_f)	71	95	175	1.34	2.46	
PAU3 (YCR104W) (_f)	180	184	443	1.02	2.46	
SKO1 (YNL167C)	43	20	101	0.47	2.35	
PRE3 (YJL001W) exon 1	112	166	241	1.48	2.15	
ORF YMR045C exon 2 (_f)	93	132	197	1.42	2.12	
ORF YNL006W	77	100	161	1.30	2.09	
MSI4 (YOR370C)	63	46	130	0.73	2.06	
ORF YPR139C	91	122	187	1.34	2.05	
SPO15 (YKR001C)	35	141	59	4.03	1.69	
HHO1 (YPL127C)	81	45	135	0.56	1.67	
ILV3 (YJR016C)	119	72	182	0.61	1.53	
ORF YBR105C	82	20	120	0.24	1.46	
LYS4 (YDR234W)	479	244	576	0.51	1.20	
ORF YOR009W	144	310	158	2.15	1.10	
NDC1 (YML031W)	113	33	115	0.29	1.02	
ORF YOL073C	143	180	88	1.26	0.62	
ORF YJL223C (_f)	134	175	81	1.31	0.60	
ORF YMR242C	1170	1227	610	1.05	0.52	
ORF YOR248W (_f)	497	422	239	0.85	0.48	
ORF YPL081W exon 1	159	135	75	0.85	0.47	
ORF YML019W	177	91	82	0.51	0.46	
ORF YOR293W exon 1 (_f)	3170	3237	1446	1.02	0.46	
ORF YMR050C exon 1 (_f)	374	263	169	0.70	0.45	
RPS26A (YGL189C)	11511	9978	4526	0.87	0.39	
ORF YNR035C	200	249	78	1.25	0.39	
ORF YEL033W	172	20	66	0.12	0.38	
TSL1 (YML100W)	103	20	39	0.19	0.38	
RPS33A (YOR167C) (_f)	1726	1899	589	1.10	0.34	
ORF YFL032W	122	98	37	0.80	0.30	
ORF YIL176C (_f)	115	99	34	0.86	0.30	
COQ2 (YNR041C)	84	115	21	1.37	0.25	
ORF YDL173W	141	136	34	0.96	0.24	
ORF YOL002C	111	151	20	1.36	0.18	
ORF YDL145C	118	74	20	0.63	0.17	
PROCESS=scaling	METHOD=bulk SOURCE=GA.sc					
PROCESS=assemble.pl	GENES=6365	SOURCE=				
PROCESS=filter	GENES=53	DIFF=80	MAX=	RAT=2		
=						

Figure 8

NAME=GA						
gene	YPD	GA	PGA	GA/YPD	PGA/YPD	
ORF YLR344W exon 1 (_i)	33	138	208	4.18	6.30	
SPO15 (YKR001C)	35	141	59	4.03	1.69	
ORF YPL080C	20	56	114	2.80	5.70	
ORF YML039W exon 2 (_f)	192	486	524	2.53	2.73	
ORF YIL101C	20	48	133	2.40	6.65	
ORF YMR143W exon 1 (_i)	385	895	964	2.32	2.50	
ORF YJR027W exon 2 (_f)	156	351	459	2.25	2.94	
ORF YOR009W	144	310	158	2.15	1.10	
ORF YHL040C	27	55	135	2.04	5.00	
PRE3 (YJL001W) exon 1	112	166	241	1.48	2.15	
ORF YHR217C (_r_i)	20	29	120	1.45	6.00	
ORF YMR045C exon 2 (_f)	93	132	197	1.42	2.12	
ORF YLL025W (_f)	251	355	693	1.41	2.76	
PHO84 (YML123C)	33	46	155	1.39	4.70	
COQ2 (YNR041C)	84	115	21	1.37	0.25	
ORF YOL002C	111	151	20	1.36	0.18	
ORF YOL080C	23	31	109	1.35	4.74	
ORF YPR139C	91	122	187	1.34	2.05	
ORF YJR029W exon 2 (_f)	71	95	175	1.34	2.46	
ORF YLR184W	66	88	214	1.33	3.24	
ORF YJL223C (_f)	134	175	81	1.31	0.60	
ORF YHR217C (_f)	20	26	120	1.30	6.00	
ORF YNL006W	77	100	161	1.30	2.09	
ATP11 (YNL315C)	51	66	135	1.29	2.65	
ORF YMR293C	28	36	114	1.29	4.07	
ORF YOL073C	143	180	88	1.26	0.62	
ORF YNR035C	200	249	78	1.25	0.39	
ORF YOR091W	59	69	148	1.17	2.51	
ORF YPR098C	37	43	203	1.16	5.49	
RPS33A (YOR167C) (_f)	1726	1899	589	1.10	0.34	
ORF YMR242C	1170	1227	610	1.05	0.52	
PAU3 (YCR104W) (_f)	180	184	443	1.02	2.46	
CYT1 (YOR065W)	91	93	257	1.02	2.82	
ORF YOR293W exon 1 (_f)	3170	3237	1446	1.02	0.46	
ORF YIL011W	153	154	460	1.01	3.01	
ORF YDL173W	141	136	34	0.96	0.24	
RPS26A (YGL189C)	11511	9978	4526	0.87	0.39	
ORF YIL176C (_f)	115	99	34	0.86	0.30	
ORF YOR248W (_f)	497	422	239	0.85	0.48	
ORF YPL081W exon 1	159	135	75	0.85	0.47	
ORF YFL032W	122	98	37	0.80	0.30	
MSI4 (YOR370C)	63	46	130	0.73	2.06	
ORF YMR050C exon 1 (_f)	374	263	169	0.70	0.45	
ORF YDL145C	118	74	20	0.63	0.17	
ILV3 (YJR016C)	119	72	182	0.61	1.53	
HHO1 (YPL127C)	81	45	135	0.56	1.67	
ORF YML019W	177	91	82	0.51	0.46	
LYS4 (YDR234W)	479	244	576	0.51	1.20	
SKO1 (YNL167C)	43	20	101	0.47	2.35	
NDC1 (YML031W)	113	33	115	0.29	1.02	
ORF YBR105C	82	20	120	0.24	1.46	
TSL1 (YML100W)	103	20	39	0.19	0.38	
ORF YEL033W	172	20	66	0.12	0.38	
PROCESS=scaling	METHOD=bulk SOURCE=GA.scf					
PROCESS=assemble.pl	GENES=6365		SOURCE=			
PROCESS=filter	GENES=53		DIFF=80		MAX=	
					RAT=2	
=						

Figure 9

# Homologous Genes Induced by Filamentation and Mating MAPK Pathways




Figure 10

Gene	WT	tec1	ste12	ste7	tec1hc	STE11-4	YPD Tule Lines
MFA1 (YDR461W)	3803	5138	20	28	3378	2262	Mating pheromone a-factor, exported from cell by Ste6p
ANB1 (YJR047C)	1285	1668	31	110	1090	39	Translation initiation factor eIF5A, contains essential lysine modification
HIS3 (YOR202W)	334	317	34	60	378	73	
MFA2 (YNL145W)	7879	6017	821	193	4780	4674	Mating pheromone a-factor, exported from cell by Ste6p
STE2 (YGL026W)	866	1169	121	178	802	598	Pheromone alpha-factor receptor, seven-transmembrane domain protein
ORF YDL120W	118	102	50	49	117	59	Mitochondrial protein involved in regulatory function and iron homeostasis, homolog of human frataxin which is defective in Friedreich's ataxia
ORF YIL121W	286	169	52	119	212	258	Member of major facilitator superfamily (MFS) multidrug resistance (MFS-MDR) protein family
ORF YOL026C	108	140	20	28	127	83	Protein of unknown function
ORF YKL120W	906	714	168	217	741	1989	Protein with similarity to members of the mitochondrial carrier (MTC) family
COS6 (YGR285C)	639	480	122	131	415	130	Protein with strong similarity to other subunit-enclosed proteins such as Cus5p, Ynf30p, Cus3p, Cus4p, Cus6p, Cus7p
CHS2 (YGR038W)	104	76	20	20	60	60	Chitin synthase II, responsible for primary septum disk
ORF YLR437C	103	48	20	20	58	34	Protein of unknown function
QRI2 (YDL105W)	102	48	21	20	78	20	Protein of unknown function
GPA1 (YHR005C)	168	124	37	51	75	39	Chemical nucleotide-binding protein alpha subunit of the pheromone response pathway
ORF YKL137W	117	59	27	30	67	55	Protein of unknown function
AGA2 (YGL032C)	299	538	69	64	342	1990	Aspartate binding subunit
ORF YHR214W (L)	107	64	25	25	104	114	Protein of unknown function (YAN066W and YHR214W code for identical proteins)
LEU1 (YGL009C)	2205	1865	518	489	1758	3671	3-hydroxyisovalate dehydratase, second step in leucine biosynthesis pathway
PDR12 (YPL058C)	198	172	47	62	115	134	Protein with similarity to Pdr3p and Cus2p, member of the ATP-binding cassette (ABC) superfamily
MEP2 (YNL142W)	258	244	65	52	151	357	Inhibitor of Cdc28p-Cln1p and Cln2p-Cln2p kinase complexes involved in cell cycle arrest for mating
ILV3 (YJR016C)	156	115	40	33	227	123	Ammonia permease of low capacity and high affinity
NOP4 (YPL043W)	979	785	256	268	1012	1158	Dihydroxyacid dehydratase (DAD), third step in valine and isoleucine biosynthesis pathway
ADE5.7 (YGL234W)	114	98	30	29	107	28	Nucleolar protein required for ribosome biogenesis, has 3 conserved RNA recognition (RRM) domains and one degenerate RNA recognition (RRM) domain
ORF YMR304C-A	611	313	137	114	467	107	Phosphoribosyltransferase, glycine ligase (GAR38c) + Phosphoribosyltransferase (GAR38c) + Phosphoribosyltransferase (GAR38c)
MSB2 (YGR014W)	72	86	20	20	110	27	Protein for which overproduction suppresses bud emergence defect of cdc24 mutant
MPT5 (YGL178W) exon 1	71	59	20	20	110	45	Protein required for high temperature growth, recovery from alpha-factor arrest, and normal lifespan of yeast cells
WCS2 (YNL289C)	129	89	37	71	257	200	Protein required for maintenance of cell wall integrity and for the stress response
RPS24B (YLR367W) exon 1	251	190	72	125	651	632	Ribosomal protein S24B (yeast S24) (p50) (YSL2/Scal 315A) (RPS24A and RPS24B code for nearly identical proteins)
STE6 (YNL209C)	617	747	186	277	134	302	Membrane transporter of ATP-binding cassette (ABC) superfamily responsible for export of a factor binding pheromone
BAR1 (YIL015W)	143	143	44	41	120	529	Serine protease that degrades alpha-factor (bortezomib)
CHA1 (YGL064C)	148	165	46	20	78	20	1-serine, -alanine deaminase (catalytic, 1-oxoethyl-thioester dehydratase)
ORF YER150W	77	124	24	21	452	623	Protein with similarity to Scd1p
ORF YMR305C	678	374	217	221	1423	1049	Protein with similarity to Bgl2p and other glucan (GLB) family
ORF YPR156C	1687	1494	541	601	115	233	Member of major facilitator superfamily (MFS) multidrug resistance (MFS-MDR) protein family
FET4 (YMR318C)	340	152	112	114	324	159	Low-affinity (L) transporter protein
MEP3 (YPR138C)	245	310	81	78	153	129	Ammonia permease of high capacity and low affinity
ORF YBR214W	168	107	56	57	126	141	Protein with similarity to pnc1 protein of S. pombe
ORF YGR151C (L)	117	94	39	43	487	146	Protein of unknown function
FUS3 (YBL018W)	398	421	134	130	318	513	Serine/threonine protein kinase of the MAP kinase family required for cell cycle arrest and for cell invasion during mating
ORF YOR203W	248	176	84	65	384	292	Protein of unknown function
	347	349	119	131			

Figure 11